P. Sini

发表

Structural heterogeneity of dermatan sulfate chains: correlation with heparin cofactor II activating properties.

C. Balduini, A. Denti, P. Sini, 1995, Thrombosis research.

An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin–polymerizing machine

G. Scita, E. Frittoli, P. P. Di Fiore, 2001, The Journal of cell biology.

The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade

C. Schnell, J. Wood, N. Hynes, 2005, Clinical Cancer Research.

Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.

J. Foekens, C. Schnell, J. Wood, 2008, Cancer research.

mTOR Inhibitor RAD 001 ( Everolimus ) Has Antiangiogenic / Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

H. Lane, C. Schnell, J. Brueggen, 2009 .

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

C. Chresta, S. Guichard, P. Sini, 2010, Autophagy.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Lisa L. Smith, C. Chresta, S. Guichard, 2010, Cancer research.

Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen.

M. Viola, A. Rossi, C. Giudici, 2002, European journal of biochemistry.

Effect of polydeoxyribonucleotides on human fibroblasts in primary culture

C. Balduini, A. Denti, P. Sini, 1999 .

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

T. Ward, C. Dive, J. Cummings, 2008, Molecular Cancer Therapeutics.

Preclinical evaluation of M 30 and M 65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

T. Ward, C. Dive, J. Cummings, 2008 .

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer

A. Paradiso, P. Chiarappa, A. Azzariti, 2011, British Journal of Cancer.

Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.

A. Ryan, N. Wright, R. Goodlad, 2012, International journal of oncology.

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

K. Smalley, Keiran S M Smalley, Manali S Phadke, 2015, Molecular Cancer Therapeutics.

Effect of polydeoxyribonucleotides on human fibroblasts in primary culture.

C. Balduini, A. Denti, P. Sini, 1999, Cell biochemistry and function.

Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation

A. Koleske, G. Scita, P. P. D. Fiore, 2004, Nature Cell Biology.

Wnt3a regulates proliferation and migration of HUVEC via canonical and non-canonical Wnt signaling pathways.

T. Schlange, N. Hynes, Ivana Samaržija, 2009, Biochemical and biophysical research communications.

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

H. Lane, G. Martiny-Baron, C. Schnell, 2009, Clinical Cancer Research.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

I. Waizenegger, G. Adolf, C. Haslinger, 2016, Molecular Cancer Therapeutics.

Role of decorin on in vitro fibrillogenesis of type I collagen

C. Balduini, A. Denti, P. Sini, 1997, Glycoconjugate Journal.

Hyaluronidase-injectable microparticles intended for the treatment of extravasation.